An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer

H. R. Naik, J. E. Lehr, K. J. Pienta

Research output: Contribution to journalArticle


Hormone refractory prostate cancel remains an incurable disease. Newer agents with more activity are required. Genistein is a flavone compound with anti-tumor activity against various tumor systems in vitro. This study is undertaken to assess the efficacy of genistein against hormone refractory prostate cancer. In vitro, genistein appears to be cytotoxic to both the rat prostate cancer cell line MAT-LyLu and the human prostate adenocarcinoma cell line, PC-3. In vivo, however, genistein failed to significantly inhibit the growth of subcutaneously implanted MAT-LyLu cells. More information regarding the pharmacokinetics and bio-availability of genistein is needed to determine if this is an active agent in human metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)2617-2619
Number of pages3
JournalAnticancer Research
Issue number6 B
StatePublished - Dec 1 1994
Externally publishedYes



  • Antitumor effects
  • Genistein
  • Isoflavones

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this